Barry Getzoff, DO
Rheumatology · Langhorne, PANPI 1265626048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 439 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 439 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- AstraZeneca$1K
- Pfizer$796
- AbbVie$684
- Novartis$492
- plus $4K from 31 others
Across 21 payments — averaging $4295.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$90K
What the payments were for
- Consulting fees$801%
- Food & beverage$10,07897%
- Education$2442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 84 | $1,970 |
| Johnson & Johnson(3 entities) | 62 | $1,483 |
| AstraZeneca | 46 | $1,198 |
| Pfizer | 59 | $796 |
| AbbVie | 37 | $684 |
| Novartis | 30 | $492 |
| ANI Pharmaceuticals, Inc. | 16 | $451 |
| Lilly USA, LLC | 9 | $386 |
| GSK | 13 | $316 |
| Genentech USA, Inc. | 13 | $274 |
| Sanofi | 7 | $230 |
| Radius Health, Inc. | 7 | $193 |
| E.r. Squibb & Sons, L.L.C. | 9 | $178 |
| UCB, Inc. | 7 | $164 |
| Biocryst US Sales Co., LLC | 1 | $127 |
| Zimmer Biomet | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $122 |
| Novo Nordisk | 1 | $115 |
| Mallinckrodt Hospital Products Inc. | 4 | $112 |
| Boehringer Ingelheim | 4 | $110 |
| Mallinckrodt Enterprises LLC | 4 | $94 |
| Boston Scientific | 1 | $85 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $83 |
| Vertos Medical, Inc. | 1 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $73 |
| Aurinia Pharma U.S., Inc. | 3 | $69 |
| Glaukos Corporation | 1 | $67 |
| Pacira Therapeutics, Inc. | 2 | $67 |
| Organon | 2 | $54 |
| Sandoz | 2 | $42 |
| Medexus Pharma, Inc. | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Bristol Myers Squibb | 1 | $25 |
| Sobi, Inc | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,402 in reported general payments places this provider in the 70th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 66 | $494,059 |
| XeljanzTofacitinib Citrate | 72 | $468,467 |
| Enbrel SureclickEtanercept | 45 | $374,778 |
| Humira PenAdalimumab | 32 | $267,523 |
| Humira(Cf) PenAdalimumab | 15 | $156,668 |
| OtezlaApremilast | 13 | $62,786 |
| MethotrexateMethotrexate Sodium | 206 | $6,866 |
| Hydroxychloroquine Sulfate | 132 | $6,100 |
| Celecoxib | 179 | $6,008 |
| Cevimeline Hcl | 24 | $3,426 |
| Clobetasol Propionate | 18 | $2,344 |
| Gabapentin | 153 | $2,127 |
| Tramadol Hcl | 204 | $1,894 |
| Duloxetine Hcl | 70 | $1,507 |
| Prednisone | 193 | $1,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $684 | $494,05966 claims |
| PfizerXeljanz | $796 | $468,46772 claims |
| AmgenOtezla | $1,970 | $62,78613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Langhorne
- Manisha NaikLanghorne$189K
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.